NeuroThera launches Phase IIb Yale site for Tourette syndrome drug candidate SCI-110

PUBT · 2d ago
NeuroThera launches Phase IIb Yale site for Tourette syndrome drug candidate SCI-110
  • NeuroThera Labs opened a U.S. site at Yale for a Phase IIb trial of SCI-110 to treat Tourette syndrome in adults.
  • Prior results were already presented from a Phase IIa study that indicated symptom improvement with acceptable safety.
  • The Phase IIb study will test whether daily oral SCI-110 reduces tics versus placebo while tracking side effects.
  • Results will be presented in the future, with tic severity assessed at weeks 12 and 26 versus baseline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608050805TNWSWRCACNPR_____1AqRFJyvK) on August 05, 2026, and is solely responsible for the information contained therein.